Drug Profile
Research programme: malaria vaccine - sanofi-aventis
Alternative Names: Orthology MalariaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Medicines for Malaria Venture; Sanofi
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Malaria in France (Parenteral, Injection)
- 05 May 2011 Early research in Malaria in France (Parenteral)
- 22 Oct 2008 Sanofi-aventis and Medicines for Malaria Venture enter into a collaboration to accelerate research and development of new antimalarial drugs